Matches in SemOpenAlex for { <https://semopenalex.org/work/W2043669396> ?p ?o ?g. }
- W2043669396 endingPage "e820" @default.
- W2043669396 startingPage "e817" @default.
- W2043669396 abstract "OBJECTIVE. Gastric acidity (GA) inhibitors, including histamine-2 receptor antagonists (H2 blockers) and proton pump inhibitors (PPIs), are the mainstay of gastroesophageal reflux disease (GERD) treatment. A prolonged GA inhibitor–induced hypochlorhydria has been suggested as a risk factor for severe gastrointestinal infections. In addition, a number of papers and a meta-analysis have shown an increased risk of pneumonia in H2-blocker–treated intensive care patients. More recently, an increased risk of community-acquired pneumonia associated with GA inhibitor treatment has been reported in a large cohort of adult patients. These findings are particularly relevant to pediatricians today because so many children receive some sort of GA-blocking agent to treat GERD. To test the hypothesis that GA suppression could be associated with an increased risk of acute gastroenteritis and pneumonia in children treated with GA inhibitors, we conducted a multicenter, prospective study. METHODS. The study was performed by expert pediatric gastroenterologists from 4 pediatric gastroenterology centers. Children (aged 4–36 months) consecutively referred for common GERD-related symptoms (for example, regurgitation and vomiting, feeding problems, effortless vomiting, choking), from December 2003 to March 2004, were considered eligible for the study. Exclusion criteria were a history of GA inhibitors therapy in the previous 4 months, Helicobacter pylori infection, diabetes, chronic lung or heart diseases, cystic fibrosis, immunodeficiency, food allergy, congenital motility gastrointestinal disorders, neuromuscular diseases, or malnutrition. Control subjects were recruited from healthy children visiting the centers for routine examinations. The diagnosis of GERD was confirmed in all patients by standard criteria. GA inhibitors (10 mg/kg ranitidine per day in 50 children or 1 mg/kg omeprazole per day in 50 children) were prescribed by the physicians for 2 months. All enrolled children were evaluated during a 4-month follow-up. The end point was the number of patients presenting with acute gastroenteritis or community-acquired pneumonia during a 4-month follow-up study period. RESULTS. We obtained data in 186 subjects: 95 healthy controls and 91 GA-inhibitor users (47 on ranitidine and 44 on omeprazole). The 2 groups were comparable for age, gender, weight, length, and incidence of acute gastroenteritis and pneumonia in the 4 months before enrollment. Rate of subjects presenting with acute gastroenteritis and community-acquired pneumonia was significantly increased in patients treated with GA inhibitors compared with healthy controls during the 4-month follow-up period. In the GA inhibitor-treated group, the rate of subjects presenting with acute gastroenteritis and community-acquired pneumonia was increased when comparing the 4 months before and after enrollment. No differences were observed between H2 blocker and PPI users in acute gastroenteritis and pneumonia incidence in the previous 4 months and during the follow-up period. On the contrary, in healthy controls, the incidence of acute gastroenteritis and pneumonia remained stable. CONCLUSIONS. This is the first prospective study performed in pediatric patients showing that the use of GA inhibitors was associated with an increased risk of acute gastroenteritis and community-acquired pneumonia in GERD-affected children. It could be interesting to underline that we observed an increased incidence of intestinal and respiratory infection in otherwise healthy children taking GA inhibitors for GERD treatment. On the contrary, the majority of the previous data showed that the patients most at risk for pneumonia were those with significant comorbid illnesses such as diabetes or immunodeficiency, and this points to the importance of GA suppression as a major risk factor for infections. In addition, this effect seems to be sustained even after the end of therapy. The results of our study are attributable to many factors, including direct inhibitory effect of GA inhibitors on leukocyte functions and qualitative and quantitative gastrointestinal microflora modification. Additional studies are necessary to investigate the mechanisms of the increased risk of infections in children treated with GA inhibitors, and prophylactic measures could be considered in preventing them." @default.
- W2043669396 created "2016-06-24" @default.
- W2043669396 creator A5007559655 @default.
- W2043669396 creator A5017816226 @default.
- W2043669396 creator A5023037339 @default.
- W2043669396 creator A5023557423 @default.
- W2043669396 creator A5025023582 @default.
- W2043669396 creator A5044203595 @default.
- W2043669396 creator A5065477321 @default.
- W2043669396 creator A5072255795 @default.
- W2043669396 creator A5080352321 @default.
- W2043669396 creator A5081179781 @default.
- W2043669396 date "2006-05-01" @default.
- W2043669396 modified "2023-10-05" @default.
- W2043669396 title "Therapy With Gastric Acidity Inhibitors Increases the Risk of Acute Gastroenteritis and Community-Acquired Pneumonia in Children" @default.
- W2043669396 cites W1526756159 @default.
- W2043669396 cites W1907775504 @default.
- W2043669396 cites W1990279350 @default.
- W2043669396 cites W2082189017 @default.
- W2043669396 cites W2091256512 @default.
- W2043669396 cites W2095092878 @default.
- W2043669396 cites W2100084977 @default.
- W2043669396 cites W2107414352 @default.
- W2043669396 cites W2113443314 @default.
- W2043669396 cites W2149675013 @default.
- W2043669396 cites W2160967161 @default.
- W2043669396 cites W3024522789 @default.
- W2043669396 cites W4232172163 @default.
- W2043669396 cites W80804953 @default.
- W2043669396 doi "https://doi.org/10.1542/peds.2005-1655" @default.
- W2043669396 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16651285" @default.
- W2043669396 hasPublicationYear "2006" @default.
- W2043669396 type Work @default.
- W2043669396 sameAs 2043669396 @default.
- W2043669396 citedByCount "343" @default.
- W2043669396 countsByYear W20436693962012 @default.
- W2043669396 countsByYear W20436693962013 @default.
- W2043669396 countsByYear W20436693962014 @default.
- W2043669396 countsByYear W20436693962015 @default.
- W2043669396 countsByYear W20436693962016 @default.
- W2043669396 countsByYear W20436693962017 @default.
- W2043669396 countsByYear W20436693962018 @default.
- W2043669396 countsByYear W20436693962019 @default.
- W2043669396 countsByYear W20436693962020 @default.
- W2043669396 countsByYear W20436693962021 @default.
- W2043669396 countsByYear W20436693962022 @default.
- W2043669396 countsByYear W20436693962023 @default.
- W2043669396 crossrefType "journal-article" @default.
- W2043669396 hasAuthorship W2043669396A5007559655 @default.
- W2043669396 hasAuthorship W2043669396A5017816226 @default.
- W2043669396 hasAuthorship W2043669396A5023037339 @default.
- W2043669396 hasAuthorship W2043669396A5023557423 @default.
- W2043669396 hasAuthorship W2043669396A5025023582 @default.
- W2043669396 hasAuthorship W2043669396A5044203595 @default.
- W2043669396 hasAuthorship W2043669396A5065477321 @default.
- W2043669396 hasAuthorship W2043669396A5072255795 @default.
- W2043669396 hasAuthorship W2043669396A5080352321 @default.
- W2043669396 hasAuthorship W2043669396A5081179781 @default.
- W2043669396 hasConcept C126322002 @default.
- W2043669396 hasConcept C187212893 @default.
- W2043669396 hasConcept C2776848118 @default.
- W2043669396 hasConcept C2776938444 @default.
- W2043669396 hasConcept C2777014526 @default.
- W2043669396 hasConcept C2777914695 @default.
- W2043669396 hasConcept C2779134260 @default.
- W2043669396 hasConcept C2780852908 @default.
- W2043669396 hasConcept C2781025758 @default.
- W2043669396 hasConcept C43270747 @default.
- W2043669396 hasConcept C71924100 @default.
- W2043669396 hasConcept C90924648 @default.
- W2043669396 hasConceptScore W2043669396C126322002 @default.
- W2043669396 hasConceptScore W2043669396C187212893 @default.
- W2043669396 hasConceptScore W2043669396C2776848118 @default.
- W2043669396 hasConceptScore W2043669396C2776938444 @default.
- W2043669396 hasConceptScore W2043669396C2777014526 @default.
- W2043669396 hasConceptScore W2043669396C2777914695 @default.
- W2043669396 hasConceptScore W2043669396C2779134260 @default.
- W2043669396 hasConceptScore W2043669396C2780852908 @default.
- W2043669396 hasConceptScore W2043669396C2781025758 @default.
- W2043669396 hasConceptScore W2043669396C43270747 @default.
- W2043669396 hasConceptScore W2043669396C71924100 @default.
- W2043669396 hasConceptScore W2043669396C90924648 @default.
- W2043669396 hasIssue "5" @default.
- W2043669396 hasLocation W20436693961 @default.
- W2043669396 hasLocation W20436693962 @default.
- W2043669396 hasOpenAccess W2043669396 @default.
- W2043669396 hasPrimaryLocation W20436693961 @default.
- W2043669396 hasRelatedWork W1963661468 @default.
- W2043669396 hasRelatedWork W1972259282 @default.
- W2043669396 hasRelatedWork W1977139604 @default.
- W2043669396 hasRelatedWork W2047172704 @default.
- W2043669396 hasRelatedWork W2135490531 @default.
- W2043669396 hasRelatedWork W2462839051 @default.
- W2043669396 hasRelatedWork W2496216674 @default.
- W2043669396 hasRelatedWork W3030928916 @default.
- W2043669396 hasRelatedWork W4234457849 @default.
- W2043669396 hasRelatedWork W2586336379 @default.
- W2043669396 hasVolume "117" @default.